CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »
This year’s Virtual Symposium was held on 3-9 October 2020 and included live and on-demand lectures, training courses, industry symposia and poster presentations.
CGRP therapies have proved more effective in clinical practice than in trials, though adverse events (AEs) and discontinuations are more common. There is potential for both rapid and delayed responses, and there appear to be additive and synergistic effects between CGRP therapies and other preventive treatments such as botulinum toxin. These were the main conclusions …
Read more »Long-term erenumab treatment up to five years has demonstrated sustained reductions in migraine frequency with no new safety signals, according to latest data from an open label treatment phase (OLTP) following a 12-week double-blind treatment phase (DBTP) in patients with episodic migraine. Of 383 patients enrolled in the OLTP, 250 switched from erenumab 70 mg …
Read more »Fewer than one in 10 patients with high frequency episodic migraine (HFEM) or chronic migraine (CM) who took part in four major galcanezumab trials exhibited ‘wearing off’ signs during the final week of each treatment cycle. This is the conclusion from an exploratory analysis of data from the EVOLVE-1 and -2, REGAIN and CONQUER trials. …
Read more »Fremanezumab has demonstrated sustained efficacy and tolerability with up to six months treatment in the Phase 3B FOCUS study of patients with episodic migraine (EM) or chronic migraine (CM) who had inadequate response to 2-4 classes of prior migraine preventive medication classes.1 A further analysis of 12-week data from the trial has shown that number …
Read more »Patients requiring inpatient treatment for constipation within 90 days of starting erenumab treatment are likely to be older (> 65 years), or to have had prior constipation or complications of constipation, or baseline constipation risk factors other than multiple sclerosis.1 These are the conclusions of an analysis carried out on 9,994 new patients aged > …
Read more »Non-clinically relevant changes have been reported in pharmacokinetic (PK) studies of atogepant coadministered with sumatriptan, acetaminophen or naproxen. In a Phase 1 pharmacokinetic study of atogepant and sumatriptan in 30 healthy adults, the median time for atogepant to achieve maximum plasma concentration (Tmax) was delayed by 1.5 hours when the drug was coadministered with sumatriptan …
Read more »Patients using ubrogepant can expect the same efficacy and tolerability in treating their migraine attacks, irrespective of whether they are taking preventive therapies. Taking erenumab or galcanezumab with ubrogepant does not appear to affect ubrogepant pharmacokinetics. These are the findings from two presentations reporting coadministration of ubrogepant and preventive therapies. Data from the ACHIEVE trials …
Read more »
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
